ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response

Rodrigo Erlich; Candis Morrison; Bong Kim; Mark R Gilbert; Saadah Alrajab

doi:10.1081/cnv-120030214

ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response

Cancer Invest. 2004;22(2):257-61. doi: 10.1081/cnv-120030214.

Authors

Rodrigo Erlich¹, Candis Morrison, Bong Kim, Mark R Gilbert, Saadah Alrajab

Affiliation

¹ Department of Oncology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave., Baltimore, MD 21224, USA. rerlich@jhmi.edu

PMID: 15199608
DOI: 10.1081/cnv-120030214

Abstract

This report describes a case of large-cell lung carcinoma with neuroendocrine features, presenting with the full clinical picture of paraneoplastic opsoclonus-myoclonus syndrome. The patient had an unexpectedly dramatic resolution of the neurologic dysfunction after receiving antineoplastic treatment. Symptom improvement paralleled a progressive decline of serum ANNA-2 antibody titers to undetectable levels.

MeSH terms

Antibodies, Antinuclear
Antibodies, Neoplasm / analysis*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / immunology*
Carcinoma, Non-Small-Cell Lung / pathology*
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / immunology*
Lung Neoplasms / pathology*
Middle Aged
Paraneoplastic Syndromes, Nervous System / drug therapy
Paraneoplastic Syndromes, Nervous System / immunology*
Paraneoplastic Syndromes, Nervous System / pathology*
Prognosis
Treatment Outcome

Substances

ANNA-2 antibody, human
Antibodies, Antinuclear
Antibodies, Neoplasm